Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Galena Biopharma Inc    GALE   US3632561086

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2014 08/15/2014 08/18/2014 08/19/2014 08/20/2014 Date
2.62(c) 2.53(c) 2.43(c) 2.33(c) 2.32 Last
1 320 302 2 594 518 2 986 829 2 941 315 1 150 242 Volume
-1.87% -3.44% -3.95% -4.12% -0.43% Change
More quotes
Company
Galena Biopharma, Inc. is a biotechnology company focused on discovering, developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. It currently develops peptide antigenbased off the shelf cancer immunotherapies for... 
Surperformance© rating of Galena Biopharma Inc
Trading Rating : Investor Rating :
More about the company
Chart GALENA BIOPHARMA INC
Duration : Period :
Galena Biopharma Inc Technical Analysis Chart | GALE | US3632561086 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 13,0 M
EBIT 2014 -50,6 M
Net income 2014 -45,6 M
Debt 2014 -
Yield 2014 -
Sales 2015 23,2 M
EBIT 2015 -38,9 M
Net income 2015 -41,6 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 21,3x
Capi. / Sales 2015 11,9x
Capitalization 275 M
More Financials
Latest news on GALENA BIOPHARMA INC
08/11 GALENA BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
08/11 GALENA BIOPHARMA : Results of Operations and Financial Condition, Financial Stat..
08/11 GALENA BIOPHARMA : Reports Second Quarter 2014 Results
08/08 Leading Health Care Stock for Small-Cap Stars is Horizon Pharma Inc. (HZNP) f..
07/29 Galena Biopharma to Report Second Quarter 2014 Financial Results on Monday, A..
07/22 GALENA BIOPHARMA : Entry into a Material Definitive Agreement, Financial Stateme..
07/22 GALENA BIOPHARMA : MonoSol Rx Enters Into Exclusive Licensing Agreement With Gal..
07/22 GALENA BIOPHARMA : Enters Into Definitive Agreement to License U.S. Rights for Z..
07/02 GALENA BIOPHARMA : Submission of Matters to a Vote of Security Holders (form 8-K..
07/01 Galena Biopharma Receives Notice of Allowance of Broad U.S. Patent for NeuVax..
06/19 Galena Biopharma to Present at the 9th Annual JMP Securities Healthcare Confe..
06/17 GALENA BIOPHARMA : Completes Enrollment in GALE-301 Phase 2a Clinical Trial in O..
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
Galena Biopharma Inc : Income Statement Evolution
More Financials
EPS Revisions
Galena Biopharma Inc : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF